Altimmune reports Q1 EPS (18c), consensus (25c)

“We continue to make significant progress across multiple fronts, as we enter a new phase for Altimmune (ALT),” said Jerry Durso, president and CEO of Altimmune. “As a result of the recent successful financing with top-tier biotech investors, we now have a strong cash position that enables us to focus on execution and delivering on our goal of bringing pemvidutide to patients with serious liver diseases and create long-term value for our shareholders. Looking ahead, we have several important milestones this year, including the initiation of the PERFORMA Phase 3 MASH trial, topline data from the RECLAIM Phase 2 AUD trial, and enrollment completion in the RESTORE Phase 2 ALD trial.”